January, the Biden administration released its proposed Medicare Advantage rates in 2026. These are the rates that the government pays insurers for the program to provide low-cost, affordable plans for seniors.

Reforms of prescription drug pricing are finally taking full effect, just in time for Donald Trump and the Republicans to wreck them.

On Jan. 20, 2025, U.S President Donald Trump rescinded an executive order signed by former President Joe Biden aimed at lowering prescription drug prices for patients on Medicare and Medicaid. Rating: Mostly True (About this rating?) What's True ...

to develop and test ways to lower drug prices for people on Medicare and Medicaid. Since former-President Joe Biden's 2022 order, CMS had been planning out and preparing to test three models to lower prices. None of them had fully gone into effect.

Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

If public opinion polls are the guide, Joe Biden has been the worst president since Richard Nixon. Here's why that may be true.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.

President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats described as an "attack" on the federal program.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.